The Schering-Plough Corp., is now approved for the maintenance treatment of asthma as a preventative therapy in patients ages four to 11 years old. Containing mometasone furoate inhalation powder, the new inhaler was previously approved as a
Our hosts explore why ketone monitoring matters, what pharmacists should know about Libre Duo, and how patient education can support proactive care management.
Mark Ey, RPh, details the patient-focused factors of the ACCESS to Pharmacy Care Program and the ways in which valued care translates to reimbursement.